Anne White to become new head of Lilly Oncology

31 August 2018
anne_white_big

Indianapolis, USA-based Eli Lilly (NYSE: LLY) has announced that Anne White is to become president of Lilly Oncology and senior vice president of Lilly, effective September 1, 2018.

She will also join the firm’s executive committee, reporting directly to chairman and chief executive officer David Ricks.

Ms White, who is currently VP of portfolio management for R&D, is replacing the outgoing Lilly Oncology chief Sue Mahony, who is retiring.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical